As mentioned before, with PEA being a substrate for FAAH, it was expected that the use of FAAH blockers could improve HD symptoms in R6/2 mice, suggesting that drugs that inhibit eCB degradation could be used to treat HD. The gene discussed is FAAH; the disease is Huntington disease.